Rational Vaccines

rationalvaccines.com

Rational Vaccines (RVx) was formed in 2015 for the purpose of offering better solutions to stop the spread of herpes and alleviate the problems faced by people suffering with unrelenting, chronic disease. Based on the life work of Dr. Bill Halford, Associate Professor, Southern Illinois University Medical School, who studied herpes simplex virus 1 and 2 (HSV-1 and HSV-2) in a laboratory setting for 25 years, RVx has developed the world’s first line of rationally-engineered live HSV-1 and HSV-2 vaccines that have been shown across 10 years of pre-clinical studies to be safe and highly immunogenic. RVx has also developed a novel type-specific diagnostic method, the ABVIC test, for serological testing of patients for HSV-1 and/or HSV-2 infection, which greatly improves upon the existing standard of care. Through the development of rationally-engineered live viral vaccines and a more accurate and reliable HSV diagnostic test, RVx is forging the path ahead to a brighter future.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

QUANTUM LEAP AND SIGNALPATH TO INTEGRATE CLINICAL TRIAL SOFTWARE INFRASTRUCTURE ACROSS I-SPY PLATFORM TRIALS

Quantum Leap, SignalPath | February 24, 2021

news image

Quantum Leap Healthcare Cooperative (Quantum Leap) and SignalPath reported a partnership today that will further enable the I-SPY platform trials with vigorous, streamlined technology infrastructure to drive the straightforwardness and efficiency of trial execution. SignalPath will integrate existing work process instruments being utilized to control the I-SPY trials into SignalPath's research operations and financial platform. In view of the public health emergency surrounding the COVID-19 ...

Read More

U.S. FDA ACCEPTS BIOHAVEN'S SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) OF NURTEC™ ODT FOR THE PREVENTIVE TREATMENT OF MIGRAINE

Biohaven Pharmaceutical Holding Company Ltd. | October 14, 2020

news image

Biohaven Pharmaceutical Holding Company Ltd. today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review its recently submitted supplemental New Drug Application (sNDA) for NURTEC™ ODT (rimegepant) for the preventive treatment of migraine. The Prescription Drug User Fee Act (PDUFA) goal date for completion of the FDA review of the preventive sNDA is set for 2Q2021. Vlad Coric, M.D., Chief Executive Officer of Biohaven commented, "Patients with mi...

Read More

Research, PHARMA TECH

OM1 RELEASES ANALYTIC REPORTS, UNCOVERING MEDICATION DISCONTINUATION IN PATIENTS

OM1 | February 06, 2023

news image

OM1, a leading real-world data, results, and technology firm focused on chronic diseases, recently announced the release of its Reasons for Discontinuation (RfD) Analytic Reports. Utilizing the OM1 Real-World Data CloudTM, Immunology Real-World Data Network, and proprietary artificial intelligence (AI) technology, the RfD reports provide difficult-to-obtain, extremely valuable discontinuation trends for cDMARDs, bDMARDs, and tsDMARDs in primary dermatologic and rheumatologic conditions. Read More

Pharma Tech

ADDITIONAL US$ 4 MILLION RECEIVED FOR NEXT DEVELOPMENT STEPS OF MEDINCELL'S 6-MONTH ACTIVE INJECTABLE BIORESORBABLE SUBCUTANEOUS CONTRACEPTIVE

MedinCell | December 01, 2022

news image

MedinCell has received an additional US$ 4 million payment from the Bill & Melinda Gates Foundation This amount is intended to finance the next steps of MedinCell’s program mdc-WWM in readiness to initiate the first clinical trial end of 2023 It follows US$ 11,8 million already received as part of the two successive grants for a total of up to US$ 22,5 million from the Bill & Melinda Gates Foundation to finance the development of the program up to phas...

Read More
news image

Pharma Tech

QUANTUM LEAP AND SIGNALPATH TO INTEGRATE CLINICAL TRIAL SOFTWARE INFRASTRUCTURE ACROSS I-SPY PLATFORM TRIALS

Quantum Leap, SignalPath | February 24, 2021

Quantum Leap Healthcare Cooperative (Quantum Leap) and SignalPath reported a partnership today that will further enable the I-SPY platform trials with vigorous, streamlined technology infrastructure to drive the straightforwardness and efficiency of trial execution. SignalPath will integrate existing work process instruments being utilized to control the I-SPY trials into SignalPath's research operations and financial platform. In view of the public health emergency surrounding the COVID-19 ...

Read More
news image

U.S. FDA ACCEPTS BIOHAVEN'S SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) OF NURTEC™ ODT FOR THE PREVENTIVE TREATMENT OF MIGRAINE

Biohaven Pharmaceutical Holding Company Ltd. | October 14, 2020

Biohaven Pharmaceutical Holding Company Ltd. today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review its recently submitted supplemental New Drug Application (sNDA) for NURTEC™ ODT (rimegepant) for the preventive treatment of migraine. The Prescription Drug User Fee Act (PDUFA) goal date for completion of the FDA review of the preventive sNDA is set for 2Q2021. Vlad Coric, M.D., Chief Executive Officer of Biohaven commented, "Patients with mi...

Read More
news image

Research, PHARMA TECH

OM1 RELEASES ANALYTIC REPORTS, UNCOVERING MEDICATION DISCONTINUATION IN PATIENTS

OM1 | February 06, 2023

OM1, a leading real-world data, results, and technology firm focused on chronic diseases, recently announced the release of its Reasons for Discontinuation (RfD) Analytic Reports. Utilizing the OM1 Real-World Data CloudTM, Immunology Real-World Data Network, and proprietary artificial intelligence (AI) technology, the RfD reports provide difficult-to-obtain, extremely valuable discontinuation trends for cDMARDs, bDMARDs, and tsDMARDs in primary dermatologic and rheumatologic conditions. Read More

news image

Pharma Tech

ADDITIONAL US$ 4 MILLION RECEIVED FOR NEXT DEVELOPMENT STEPS OF MEDINCELL'S 6-MONTH ACTIVE INJECTABLE BIORESORBABLE SUBCUTANEOUS CONTRACEPTIVE

MedinCell | December 01, 2022

MedinCell has received an additional US$ 4 million payment from the Bill & Melinda Gates Foundation This amount is intended to finance the next steps of MedinCell’s program mdc-WWM in readiness to initiate the first clinical trial end of 2023 It follows US$ 11,8 million already received as part of the two successive grants for a total of up to US$ 22,5 million from the Bill & Melinda Gates Foundation to finance the development of the program up to phas...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us